Create a free Feed & Grain account to continue reading

Kerry Acquires Enzyme Biotechnology Companies

Enzymes increasingly play a vital role as biocatalysts that deliver many benefits

Kerry group logo

Kerry has made two significant biotechnology acquisitions that will expand its expertise, technology portfolio and manufacturing capabilities.

The company has reached agreement to acquire the leading biotechnology innovation company, c-LEcta while also confirming that it has acquired the Mexican-based enzyme manufacturer, Enmex.

c-LEcta is a leading biotechnology innovation company specializing in precision fermentation, optimized bio-processing and bio-transformation for the creation of high-value targeted enzymes and ingredients.

Based in Leipzig, Germany, and employing over 100 people, c-LEcta has established itself as a leading innovator in disruptive new sciences for the pharmaceutical market, with a strong pipeline of functional bioactives across food, beverage and other consumer markets.

Enmex is a well-established enzyme manufacturer based in Mexico, supplying multiple bio-process solutions for food, beverage and animal nutrition markets.

With a long history of partnering with global customers, Enmex has a complementary enzyme portfolio and a strong manufacturing infrastructure, which will extend Kerry’s fermentation and enzyme manufacturing capabilities into Latin America.

“The food and pharmaceutical industries are on the cusp of a new wave of innovation where new developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors," says Dr. Albert McQuaid, Chief Science and Technology Officer of Kerry.

McQuaid notes c-LEcta is a leader in these new technologies, which includes fermentation-based products such as disruptive new enzymes, and the strategically compelling combination with Kerry will accelerate our innovation capabilities in enzyme engineering, fermentation and bio-process development.

"Our broad market reach across food and pharma markets, combined with our deep enzyme applications expertise and integrated ingredient technology design, will enable and accelerate the growth potential of c-LEcta’s strong portfolio and technology capabilities while also supporting us in the creation of tastier, more sustainable and healthier products," says McQuaid.

Regarding the acquisition of Enmex, Neil Cracknell, CEO of Kerry Applied Health and Nutrition, said enzymes are increasingly playing a vital role as biocatalysts in the food, beverage and pharmaceutical industries, where they deliver many benefits, including improved product quality, increased process efficiency and reduced food waste, through both minimization of waste and valorization of waste streams.

"This strategic acquisition of Enmex will complement Kerry’s existing enzyme portfolio and build on our strength in enzymes for modifying cereals and grains," says Cracknell.

"We see enzymes playing a critical role in helping achieve Kerry’s vision to create a world of sustainable nutrition, which is about providing better nutrition, with better processes, which have less impact on our earth’s resources.”

Page 1 of 202
Next Page